- Home
- RIV vs MXCT Comparison
RIV vs MXCT Comparison
Compare RIV & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIV
- MXCT
- Stock Information
- Founded
- RIV 2015
- MXCT 1999
- Country
- RIV United States
- MXCT United States
- Employees
- RIV N/A
- MXCT N/A
- Industry
- RIV Finance Companies
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RIV Finance
- MXCT Health Care
- Exchange
- RIV Nasdaq
- MXCT Nasdaq
- Market Cap
- RIV 235.3M
- MXCT 239.2M
- IPO Year
- RIV N/A
- MXCT 2021
- Fundamental
- Price
- RIV $12.14
- MXCT $2.26
- Analyst Decision
- RIV
- MXCT Strong Buy
- Analyst Count
- RIV 0
- MXCT 1
- Target Price
- RIV N/A
- MXCT $9.00
- AVG Volume (30 Days)
- RIV 87.6K
- MXCT 1.3M
- Earning Date
- RIV 01-01-0001
- MXCT 05-07-2025
- Dividend Yield
- RIV 12.85%
- MXCT N/A
- EPS Growth
- RIV N/A
- MXCT N/A
- EPS
- RIV N/A
- MXCT N/A
- Revenue
- RIV N/A
- MXCT $37,675,000.00
- Revenue This Year
- RIV N/A
- MXCT $8.82
- Revenue Next Year
- RIV N/A
- MXCT $21.12
- P/E Ratio
- RIV N/A
- MXCT N/A
- Revenue Growth
- RIV N/A
- MXCT N/A
- 52 Week Low
- RIV $9.63
- MXCT $2.10
- 52 Week High
- RIV $12.43
- MXCT $5.26
- Technical
- Relative Strength Index (RSI)
- RIV 64.83
- MXCT 42.10
- Support Level
- RIV $11.92
- MXCT $2.18
- Resistance Level
- RIV $12.06
- MXCT $2.40
- Average True Range (ATR)
- RIV 0.15
- MXCT 0.12
- MACD
- RIV -0.00
- MXCT 0.02
- Stochastic Oscillator
- RIV 74.68
- MXCT 53.33
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.